Mylotarg (gemtuzumab ozogamicin) 5 mg in a 20 mg vial

Manufacturer: American Home Products   

Indication(s):  For treatment of patients 60 or older (encompasses 75% of AML patients) in first relapse with CD33-positive acute myeloid leukemia (AML) who are not considered candidates for cytotoxic chemotherapy.

Administration:  Lyophilized powder preparation for intravenous injection

Pharmacology:  Cytotoxic agent specific for the CD33 antigen, a glycoprotein commonly expressed by myeloid leukemia cells.  The substance calicheamicin, which is attached to the antibody, exerts its cytotoxic effects at the target site.

WebRx Editorial Notes:  Mylotarg™ is the first antibody-targeted chemotherapy agent using monoclonal antibody technology.  Mylotarg™ consists of an anticancer drug attached to a monoclonal antibody that homes in on AML cells.  The most common side effects associated with Mylotarg™ are fever and chills immediately following the infusion.  Neutropenia may also occur.  This drug can be administered on an outpatient basis and represents an important milestone in the emerging science of biotechnology.

©2000, 2001 WebRx Pharmacy Palace